BACKGROUND: The androgen receptor (AR) signaling pathway has been well demonstrated to play a crucial role in the development, progression, and drug resistance of prostate cancer. Although the current anti-androgen therapy could significantly benefit prostate cancer patients initially, the efficacy of the single drug usually lasts for a relatively short period, as drug resistance quickly emerges. METHODS: We have performed an unbiased bioinformatics analysis using the RNA-seq results in 22Rv1 cells to identify the cell response toward Dip G treatment. The RNA-seq results were validated by qRT-PCR. Protein levels were detected by western blot or staining. Cell viability was measured by Aquabluer and colony formation assay. RESULTS: Here, we identified that Diptoindonesin G (Dip G), a natural extracted compound, could promote the proteasome degradation of AR and polo-like kinase 1 (PLK1) through modulating the activation of CHIP E3 ligase. Administration of Dip G has shown a profound efficiency in the suppression of AR and PLK1, not only in androgen-dependent LNCaP cells but also in castration-resistant and enzalutamide-resistant cells in a CHIP-dependent manner. Through co-targeting the AR signaling, Dip G robustly improved the efficacy of HSP90 inhibitors and enzalutamide in both human prostate cancer cells and in vivo xenograft mouse model. CONCLUSIONS: Our results revealed that Dip G-mediated AR degradation would be a promising and valuable therapeutic strategy in the clinic.
BACKGROUND: The androgen receptor (AR) signaling pathway has been well demonstrated to play a crucial role in the development, progression, and drug resistance of prostate cancer. Although the current anti-androgen therapy could significantly benefit prostate cancer patients initially, the efficacy of the single drug usually lasts for a relatively short period, as drug resistance quickly emerges. METHODS: We have performed an unbiased bioinformatics analysis using the RNA-seq results in 22Rv1 cells to identify the cell response toward Dip G treatment. The RNA-seq results were validated by qRT-PCR. Protein levels were detected by western blot or staining. Cell viability was measured by Aquabluer and colony formation assay. RESULTS: Here, we identified that Diptoindonesin G (Dip G), a natural extracted compound, could promote the proteasome degradation of AR and polo-like kinase 1 (PLK1) through modulating the activation of CHIP E3 ligase. Administration of Dip G has shown a profound efficiency in the suppression of AR and PLK1, not only in androgen-dependent LNCaP cells but also in castration-resistant and enzalutamide-resistant cells in a CHIP-dependent manner. Through co-targeting the AR signaling, Dip G robustly improved the efficacy of HSP90 inhibitors and enzalutamide in both human prostate cancer cells and in vivo xenograft mouse model. CONCLUSIONS: Our results revealed that Dip G-mediated AR degradation would be a promising and valuable therapeutic strategy in the clinic.
Authors: Jie Li; Ruixin Wang; Yifan Kong; Meaghan M Broman; Colin Carlock; Long Chen; Zhiguo Li; Elia Farah; Timothy L Ratliff; Xiaoqi Liu Journal: Mol Cancer Ther Date: 2017-01-09 Impact factor: 6.261
Authors: Jie Li; Anju Karki; Kurt B Hodges; Nihal Ahmad; Amina Zoubeidi; Klaus Strebhardt; Timothy L Ratliff; Stephen F Konieczny; Xiaoqi Liu Journal: Mol Cell Biol Date: 2015-10-05 Impact factor: 4.272
Authors: Rong Hu; Thomas A Dunn; Shuanzeng Wei; Sumit Isharwal; Robert W Veltri; Elizabeth Humphreys; Misop Han; Alan W Partin; Robert L Vessella; William B Isaacs; G Steven Bova; Jun Luo Journal: Cancer Res Date: 2009-01-01 Impact factor: 12.701
Authors: Roberta Ferraldeschi; Jonathan Welti; Marissa V Powers; Wei Yuan; Tomoko Smyth; George Seed; Ruth Riisnaes; Somaieh Hedayat; Hannah Wang; Mateus Crespo; Daniel Nava Rodrigues; Ines Figueiredo; Susana Miranda; Suzanne Carreira; John F Lyons; Swee Sharp; Stephen R Plymate; Gerhardt Attard; Nicola Wallis; Paul Workman; Johann S de Bono Journal: Cancer Res Date: 2016-05-01 Impact factor: 12.701